Document › Details
Omeicos Therapeutics GmbH. (4/15/15). "Press Release: Omeicos Therapeutics Raises EUR 6.2 Million in Series A to Advance Lead Candidate in Atrial Fibrillation". Berlin.
OMEICOS Therapeutics, a biopharmaceutical company developing first-in-class small molecule therapeutics for the prevention and treatment of cardiovascular diseases including atrial fibrillation (AF), today announced that it has raised EUR 6.2 million in a Series A round. Participating in the round were Vesalius Biocapital II S.A. SICAR, acting as lead; a SMS Group Company; VC Fonds Technologie Berlin; Hightech Gruenderfonds II GmbH & Co. KG (HTGF); and KfW Group. As part of the financing round, the company has received subsidies of EUR 550,000 via Ascenion’s Spinnovator, a grant program supported by the German Ministry of Education and Research (BMBF).
“The growing population of AF patients is faced with outdated and extremely limited medical treatment options. Current treatments have insufficient efficacy, risk of severe side effects, and are unable to reduce patient mortality,” said Dr. Robert Fischer, Chief Scientific Officer of OMEICOS Therapeutics. “We are grateful for the recognition from our investors that OMEICOS has the potential to develop truly novel drugs to prevent and treat severe cardiovascular diseases such as AF.”
The company’s novel therapeutic strategy is based on synthetic derivatives of natural metabolites of omega-3 fatty acids that have a strong antiarrhythmic effect. So far, approaches to make omega-3 fatty acids therapeutically effective have not been particularly successful due to the instability of their bioactive metabolites. OMEICOS has managed to overcome this hurdle by developing synthetic molecules that are equally potent as natural metabolites, but much more stable, making them suitable as orally available therapeutics.
Unlike other antiarrhythmic drugs, OMEICOS’ compounds activate an endogenous cardio-protective signaling pathway that stabilizes heart rhythm. In addition, the compounds are expected to provide curative effects to diseased hearts by preventing electrical and structural remodeling, a common cause of heart disease and sudden cardiac death. OMEICOS’ proprietary platform has high potential for further development in additional therapeutic indications in the cardiovascular area as well as in chronic inflammatory diseases.
“With their unique technology and seasoned team of experts, we believe that OMEICOS will fill the existing gap in AF treatment,” added Dr. Christian Schneider of Vesalius Biocapital Partners. “We are happy to support OMEICOS by leading such a strong syndicate of private and public investors and look forward to working with the company to advance its lead candidate through the pre-clinic into clinical development.”
Following the closing of the financing round, Christian Schneider and Gaston Matthyssens of Vesalius Biocapital Partners, Peter Seiler of SMS Group, Ute Mercker of VC Fonds Technologie Berlin, Martin Pfister of Hightech Gruenderfonds II GmbH & Co. KG, and co-founder Wolf-Hagen Schunck have joined the OMEICOS Supervisory Board.
About Atrial Fibrillation
Atrial fibrillation (AF) is the most common cardiac arrhythmia in humans. AF is characterized by an irregular heart rhythm originating from the heart’s upper chambers, resulting in inefficient blood pumping. AF leads to a significant reduction in quality of life, increases the risk of stroke, raises the risk of heart failure, and doubles the risk of death.
OMEICOS Therapeutics is a spin-off company from the Max Delbrueck Center for Molecular Medicine (MDC) in Berlin, co-founded and managed by Dr. Robert Fischer (Managing Director) and Dr. Karen Uhlmann. The company is developing oral, first-in-class, small molecules for the prevention and treatment of cardiovascular diseases, initially focusing on AF. The company’s novel, small molecule AF therapy is based on proprietary synthetic analogues of omega-3 fatty acid metabolites. The technology was originally discovered and developed by a research team under the supervision of Dr. Wolf Schunck and Dr. Dominik Mueller at MDC and Dr. John R. Falck at the University of Texas Southwestern Medical Center. OMEICOS’ lead candidate is envisioned for oral, once-daily treatment for patients with paroxysmal and persistent AF, with and without structural heart disease, for maintenance of sinus rhythm. www.omeicos.com
A German version of this press release is available at www.omeicos.com.
OMEICOS Therapeutics GmbH
Dr. Robert Fischer, +49 (0) 30 9489 4810
Chief Scientific Officer and Managing Director
MacDougall Biomedical Communications
Gretchen Schweitzer or Blair Atkinson, +49 (0) 89 2424 3494 or +49 (0) 151 2348 2513
Record changed: 2017-04-02
More documents for Omeicos Therapeutics GmbH
-  Omeicos Therapeutics GmbH. (3/1/17). "Press Release: Omeicos Announces First Closing of €8.3 Million Series B Financing Round and the Initiation of Phase 1 Clinical Trial". Berlin....
-  Omeicos Therapeutics GmbH. (11/2/15). "Press Release: Omeicos Receives BMBF Research Grant to Advance its Novel Approach to Treat Atrial Fibrillation". Berlin....
-  Omeicos Therapeutics GmbH. (5/5/15). "Press Release: Omeicos Appoints Dr. Ulrich Dauer as Chief Executive Officer". Berlin....
-  High-Tech Gründerfonds Management GmbH. (12/12/13). "Press Release: Omeicos Therapeutics – Novel Therapy for the Treatment of Atrial Fibrillation". Berlin & Bonn....
To subscribe to our free, monthly newsletter for the life sciences in German-speaking Europe (DE, AT & CH), please send an e-mail to firstname.lastname@example.org and simply fill the subject line with the word »LSG newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)